Mifamurtide (sodium hydrate)

Mifamurtide (MTP-PE; CGP 19835) sodium hydrate is the sodium hydrate of mifamurtide. Mifamurtide is a nonspecific immunomodulator that acts by stimulating immune responses by activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and is used as an insulin sensitizer and may also be used in osteosarcoma research[1][2][3].

Product Specifications

CAS Number

[838853-48-8]

Product Name Alternative

MTP-PE (sodium hydrate) ; L-MTP-PE (sodium hydrate) ; CGP 19835 (sodium hydrate)

UNSPSC

12352211

Hazard Statement

H302-H312-H332

Target

NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mifamurtide-sodium-hydrate.html

Solubility

10 mM in DMSO

Smiles

CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O[Na])=O)=O.[H]O[H].[x]

Molecular Formula

C59H108N6O19P.xH2O.Na

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6 (3) :677-89.|[2]Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25 (5) :1063-1074.e3.|[3]Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9 (2) : p. 131-5.